2seventy bio (TSVT) Expected to Announce Quarterly Earnings on Wednesday

2seventy bio (NASDAQ:TSVT - Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $13.96 million for the quarter.

2seventy bio (NASDAQ:TSVT - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.11. The company had revenue of $22.94 million during the quarter, compared to the consensus estimate of $13.96 million. 2seventy bio had a negative return on equity of 53.65% and a negative net margin of 207.25%. On average, analysts expect 2seventy bio to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

2seventy bio Stock Performance

Shares of NASDAQ TSVT traded down $0.01 during trading hours on Friday, hitting $4.99. The stock had a trading volume of 347,586 shares, compared to its average volume of 621,312. The firm's 50-day moving average price is $4.79 and its two-hundred day moving average price is $3.77. 2seventy bio has a 52 week low of $2.29 and a 52 week high of $5.30. The company has a market capitalization of $265.61 million, a P/E ratio of -2.68 and a beta of 1.04.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on TSVT shares. Morgan Stanley cut their price target on shares of 2seventy bio from $6.00 to $5.00 and set an "equal weight" rating on the stock in a report on Friday, March 14th. Weiss Ratings reissued a "sell (e+)" rating on shares of 2seventy bio in a report on Thursday, April 24th. Leerink Partnrs lowered 2seventy bio from a "strong-buy" rating to a "hold" rating in a report on Tuesday, March 11th. Finally, Leerink Partners reiterated a "market perform" rating and set a $5.00 price target (down previously from $9.00) on shares of 2seventy bio in a report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, four have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $5.60.

Insider Activity at 2seventy bio

In other 2seventy bio news, major shareholder Global Healthcare Master Kynam sold 5,142,111 shares of the firm's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $4.93, for a total value of $25,350,607.23. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO William D. Baird III sold 5,092 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $4.95, for a total transaction of $25,205.40. Following the transaction, the chief executive officer now directly owns 1,121,034 shares of the company's stock, valued at $5,549,118.30. This represents a 0.45 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,152,093 shares of company stock worth $25,400,018 in the last 90 days. 7.20% of the stock is owned by company insiders.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.